News
Article
Author(s):
Tapcom is a preservative-free, fixed-combination eye drop of tafluprost 0.0015% and timolol 0.5% for lowering intraocular pressure.
(Image Credit: AdobeStock/millaf)
Santen Pharmaceutical has received approval of its marketing authorization application from the National Medical Products Administration (NMPA) of China for tafluprost/timolol maleate (Tapcom) for lowering intraocular pressure (IOP) of patients with open-angle glaucoma or ocular hypertension.
Tapcom is a preservative-free, fixed-combination eye drop of tafluprost 0.0015% and timolol 0.5%. According to the company, Tapcom will be the first preservative-free ophthalmic combination formulation in China containing a first-line prostaglandin derivative.
The two active ingredients have different mechanisms of action on aqueous humor dynamics to lower the IOP. Tafluprost is a prostanoid FP receptor agonist and promotes aqueous humor outflow, while timolol maleate is a nonselective β-receptor blocker and reduces aqueous humor production.
Peter Sallstig, chief medical officer of Santen Pharmaceutical, commented on the approval in a press release from the company.
"Glaucoma remains the leading cause of irreversible blindness worldwide, deeply impacting the quality of life of many patients. Therefore, Santen has prioritized glaucoma as a key therapeutic focus, dedicating ourselves to the development of treatments that meets patients’ needs and the delivery of high-quality ophthalmic drugs. The approval of Tapcom in China represents a significant milestone, offering new treatment options for Chinese glaucoma patients and advancing the field of glaucoma care,” said Sallstig.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
2 Commerce Drive
Cranbury, NJ 08512